Recombinant protein · Agonist of Interferon alpha receptor · developed by Vir Biotechnology
Pegylated Interferon Alfa is a covalent conjugate of recombinant interferon alpha and polyethylene glycol. It binds cell-surface interferon receptors, driving gene transcription that mediates antiviral and immune-modulating effects, and is being studied in chronic hepatitis B virus infection. The polyethylene glycol moiety extends the duration of its activity.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06491563 | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection | Completed | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
For Treatment of Chronic Hepatitis B Virus Infection
Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.
See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VIR catalysts and pipeline →